The stem-cell committee is drawing up rules for the ownership and control of discoveries made by businesses, universities and research institutions that get some of the $3 billion in public money for stem-cell research. Already biotech executives are huffing and puffing about any requirement that fair-public-benefit provisions be linked to the grants.
Their remarks at the most recent Intellectual Property Task Force meeting were little more than a blustering attempt to cow Californians into believing that needed stem-cell research won't happen unless the game is played by biotech's rules. Don't believe them.
Genentech Executive Vice President Stephen Juelsgaard said the biotech industry ``simply wouldn't engage'' if the California Institute for Regenerative Medicine (CIRM) requires companies to share the rewards of Proposition 71 stem-cell research grants. Never mind that California taxpayers are putting up $3...